Royal Brompton Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Boehringer Ingelheim· Source

• Not yet recruiting

  SPutum Induction and Nebuliser deviCEs for Patients With CF

  NCT07879651· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis

  NCT07502677· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  Corticosteroid Tapering in Sarcoidosis

  NCT07498842· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study

  NCT06939374· Cryotherapeutics SA· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Rein Therapeutics· Source

• Not yet recruiting

  A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis

  NCT07402434· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

  NCT07332117· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

  NCT06891755· Apreo Health, Inc.· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979362· Phase 2· Novo Nordisk A/S· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Calluna Pharma AS· Source

• Recruiting

  A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring

  NCT06797206· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in Neuromuscular Disease or Neurodisability

  NCT06134401· Imperial College London· Source

• Active, not recruiting

  A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

  NCT06962852· Phase 1/2· Boehringer Ingelheim· Source

• Recruiting

  Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis

  NCT06940531· Alexander Horsley· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  NCT06925750· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

  NCT06846554· Phase 2· Apollo Therapeutics Ltd· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Active, not recruiting

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

  NCT06460506· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Exploring How Viral Infections Affect People With Chronic Lung Disease

  NCT06625944· Imperial College London· Source

• Enrolling by invitation

  Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

  NCT06472362· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

  NCT06423690· Snipe Medical· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

  NCT06559150· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source

• Active, not recruiting

  YOGA-CF (Yoga Outcomes Get Assessed in Cystic Fibrosis)

  NCT06120465· Royal Brompton & Harefield NHS Foundation Trust· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

  NCT06035120· Pulmonx Corporation· Source

• Active, not recruiting

  Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)

  NCT06181240· Bolt Medical· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Active, not recruiting

  Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema

  NCT05949645· Apreo Health, Inc.· Source

• Recruiting

  RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

  NCT05568069· University Hospital Southampton NHS Foundation Trust· Source

• Active, not recruiting

  Closed-loop for People Living With Cystic Fibrosis Related Diabetes

  NCT05562492· University of Cambridge· Source

• Recruiting

  Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

  NCT05496998· Medtronic Cardiovascular· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  The CATALINA Study

  NCT05008081· Wim Janssens· Source

• Active, not recruiting

  The Euro-CRAFT Registry

  NCT05805462· CoreAalst BV· Source

• Active, not recruiting

  Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

  NCT05570058· Phase 2· Redx Pharma Ltd· Source

• Recruiting

  Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases

  NCT05329350· Occlutech International AB· Source

• Recruiting

  The "Global Paradise System" Registry

  NCT05027685· ReCor Medical, Inc.· Source

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Shockwave Medical, Inc.· Source

• Active, not recruiting

  A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT04819100· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

  NCT07218029· Phase 3· Merck Sharp & Dohme LLC· Source

Showing 50 of 57.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis6 recruiting
• Cystic fibrosis5 recruiting
• Bronchiectasis4 recruiting
• COPD3 recruiting
• Heart failure3 recruiting
• Coronary artery disease2 recruiting
• Dilated cardiomyopathy2 recruiting
• High blood pressure2 recruiting
• Pulmonary arterial hypertension2 recruiting
• ALS (motor neurone disease)1 recruiting
• Cerebral palsy1 recruiting
• Congenital heart disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Lung cancer1 recruiting
• Sarcoidosis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias

  NCT06661278· Royal Brompton & Harefield NHS Foundation Trust· Source

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  Radial Artery Assessment in Surgical Coronary Revascularisation

  NCT06433960· Papworth Hospital NHS Foundation Trust· Source

• Completed

  A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

  NCT06478706· Phase 2· Enterprise Therapeutics Ltd· Source

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Kors van der Ent· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Trevi Therapeutics· Source

• Withdrawn

  A40 Expiratory Flow Limitation Registry

  NCT04419428· Philips Clinical & Medical Affairs Global· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Withdrawn

  A Study to Investigate Leramistat in Patients With IPF

  NCT05951296· Phase 2· Modern Biosciences Ltd· Source

• Completed

  A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

  NCT05954988· Phase 1· Rein Therapeutics· Source

• Completed

  Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

  NCT05882357· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

  NCT05668741· Phase 1/2· Vertex Pharmaceuticals Incorporated· Source

• Terminated

  Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

  NCT05667662· Phase 2· Pulmatrix Inc.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Examining the Effects of Mitochondrial Oxidative Stress in DCM

  NCT05410873· Phase 2· Imperial College London· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

  NCT05153317· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  VIVO European Observational Registry

  NCT04990089· Catheter Precision. Inc.· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

  NCT04559464· Pulmonx Corporation· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

  NCT04533022· Phase 2· Vicore Pharma AB· Source

• Completed

  Benralizumab Exacerbation Study

  NCT04102800· Phase 4· NHS Greater Glasgow and Clyde· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Asthma64 works · 2 trials
• Congenital heart disease56 works · 1 trial
• Cystic fibrosis49 works · 18 trials
• Bronchiectasis33 works · 4 trials
• Idiopathic pulmonary fibrosis28 works · 19 trials
• COPD23 works · 7 trials
• Sarcoidosis18 works · 1 trial
• Ventricular tachycardia16 works · 2 trials
• Pulmonary arterial hypertension13 works · 8 trials
• Myocarditis12 works · 0 trials
• Dilated cardiomyopathy11 works · 3 trials